Amazon Biotech asks FDA to approve planned trial of AMZ0026 for HIV

New York, April 18 - Amazon Biotech, Inc. said it has filed with the Food and Drug Administration a protocol to test AMZ0026 as an HIV drug to delay onset of full-blown AIDS.

The study is designed to include 60 non-symptomatic HIV-infected subjects who have not been recently treated with any AIDS medications.

AMZ0026 versus a placebo will be administered for a six-month treatment period, during which primary endpoint parameters will be monitored, including T Cell increases and the amount of HIV virus in the bloodstream.

The drug formulation is based upon Amazon's philosophy of combining several active ingredients and using whole plant pharmaceutical drug technology to create a natural, healthier pharmaceutical drug.

Amazon Biotech is a New York-based natural plant pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.